Registry for the use of NOACs in patients with Atrial Fibrillation or Venous Thromboembolism
Official title: Outcomes regiStry for Non-vitamin k Antagonist Oral anticoagUlants treatmeNt in variouS tHrombotIc dIseases for Better cliNical practicE (SUNSHINE)
Run by Henan Provincial People's Hospital · NCT05378308 · Data updated 2026-11-12
This study is looking to see how well new blood thinners called NOACs work for people with Atrial Fibrillation or blood clots, by tracking their treatment and outcomes over time.
Quick facts
| Study type | Observational |
|---|---|
| Sex | All |
| Enrollment | 5000 (estimated) |
| Sponsor | Henan Provincial People's Hospital Academic / other |
| Locations | 1 site (Zhengzhou, Henan) |
| Status | Recruiting |
| Started | June 6, 2022 |
| Main results expected | May 31, 2027 |
| Study ends | May 31, 2027 |
| Registry record updated | June 9, 2022 |
| Trial ID | NCT05378308 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Ideal candidates include patients clinically diagnosed with Atrial Fibrillation or Venous Thromboembolism who have been using oral anticoagulants within the last three months.
✕Probably not a fit
Patients with AF due to reversible causes, valvular AF, or those participating in other clinical trials may not benefit from this registry.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
The SUNSHINE registry is a multicenter, prospective, observational registry designed to assess the use and outcomes of non-vitamin K antagonist oral anticoagulants (NOACs) in patients with Atrial Fibrillation (AF) or Venous Thromboembolism (VTE). It will collect and analyze data from medical records to evaluate the safety and effectiveness of NOACs in routine clinical practice. The registry aims to enroll approximately 5,000 patients over a period of five years, focusing on treatment patterns, clinical courses, and outcomes associated with NOAC therapy. The study will also compare patients newly anticoagulated with NOACs versus those using vitamin K antagonists (VKAs).
Why it matters
Potential benefit: If successful, this registry could provide valuable insights into the safety and effectiveness of NOACs, potentially improving treatment strategies for patients with AF and VTE.
How similar studies have gone: Other studies have shown success in utilizing observational registries to assess the outcomes of anticoagulant therapies, making this approach both relevant and valuable.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: * Patients with clinically diagnosed with AF (eg, by electrocardiogram, Holter monitoring, implanted device, etc) or VTE (initial or recurrent acute VTE) * Patients who use OACs therapy (including NOAC or VKA) within the preceding 3 months * Patients can be enrolled from both inpatient or outpatient settings Exclusion Criteria: * AF resulting from reversible cause factors (e.g., thyroid disease, postoperative AF) * Patients with a diagnosis of valvular AF (valvular AF mainly refers to patients with AF that have either rheumatic valvular disease \[predominantly mitral stenosis\] or mechanical heart valves) * Patients participating in an ongoing clinical trial in AF or VTE * Have Multiple anticoagulation indications apart from AF or VTE * Patients with incomplete information (illogical data, missing or insufficient data)
Where it's running
-
Henan Provincial People's Hospital
Zhengzhou, Henan, China Recruiting
Study contacts
- Study coordinator: Shujuan Zhao
- Email: 49800425@qq.com
- Phone: 0086-13837101436
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
Evaluating DOAC levels in Chinese patients with atrial fibrillation
This study is testing how stopping blood-thinning medication for a short time affects Chinese patients with atrial fibrillation to see if it's safe for them during medical procedures.
-
Survey on patients using anticoagulant medications
This study is looking at how well different blood-thinning medications work and their safety for adults who are starting or changing their anticoagulant treatment.
-
AI-based tools to help diagnose, treat and predict stroke outcomes across multiple hospitals
This study tests AI-powered tools on real-world stroke patients to see if they can improve pre-hospital triage, diagnosis, and outcome prediction while data stay securely within each hospital.
-
DoACs vs LMWH for blood flow after knee replacement
This study tests whether rivaroxaban, apixaban, or LMWH work differently to support blood flow in the legs after total knee replacement in adults.
-
Left-atrial Fibrosis in Persistent Atrial Fibrillation and Its Comorbidities
This study tests how comorbid conditions like sleep apnea and primary aldosteronism relate to left-atrial fibrosis and AF recurrence in patients undergoing ablation.
-
Dual Energy ablation with SmartTouch SF catheter in persistent atrial fibrillation
This study tests a pulsed field and radiofrequency ablation system to treat persistent atrial fibrillation in adults who have not responded well to prior medications.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.